Lori Anne Kunkel - 17 Dec 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
17 Dec 2025
Net transactions value
+$17,873
Form type
4
Filing time
19 Dec 2025, 17:58:14 UTC
Previous filing
09 Dec 2025
Next filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kunkel Lori Anne Director C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 19 Dec 2025 0001536368

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $17,873 +15,958 +108% $1.12 30,712 17 Dec 2025 Direct
holding ELVN Common Stock 31,172 17 Dec 2025 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -15,958 -81% $0.000000 3,741 17 Dec 2025 Common Stock 15,958 $1.12 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.
F2 All of the shares subject to this option are fully vested and exercisable as of the date hereof.